CLINICAL TRIALS PROFILE FOR PROPYLTHIOURACIL
✉ Email this page to a colleague
All Clinical Trials for propylthiouracil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00677469 ↗ | Low Doses of Cholestyramine in the Treatment of Hyperthyroidism | Completed | Shiraz University of Medical Sciences | N/A | 2007-07-01 | The enterohepatic circulation of thyroid hormones is increased in thyrotoxicosis.Bile-salt sequestrants (ionic exchange resins) bind thyroid hormones in the intestine and thereby increase their fecal excretion. Based on these observations, the use of cholestyramine has been tried. The present study evaluates the effect of low doses of cholestyramine as an adjunctive therapy in the management of hyperthyroidism |
| NCT00946296 ↗ | Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease | Completed | University of Massachusetts, Worcester | Phase 4 | 2005-04-01 | The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease. |
| NCT01056419 ↗ | The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy | Unknown status | Ankara University | Phase 4 | 2009-01-01 | The relationship between the method of the treatment of hyperthyroidism due to Graves' disease and the course of Graves' ophthalmopathy is debated. The investigators aimed to compare the results of total thyroidectomy done in 6 months following the appearance of the symptoms of ophthalmopathy and the antithyroid drug therapy in patients with moderate to severe Graves' ophthalmopathy. The inclusion criteria: 1)Hyperthyroidism and moderate to severe Graves' ophthalmopathy within 6 months, 2)Thyroid volumes greater than or equal to 15 mL in thyroid ultrasonography, 3)Patients taking no treatment except local medications for Graves' ophthalmopathy, 4)Clinical activity score of 3/7 or more, proptosis greater than or equal to 21 mm in one eye or 2 mm difference between two eyes, presence of diplopia, the opening of the eye lid greater than or equal to 9 mm. All patients will be treated with antithyroid drug until TSH levels of the patients are between 0.4-1. During this period all the patients will take pulse methyl prednisolone treatment of a total dose of 4.5 gr. After pulse steroid treatment the patients will be randomised to two groups: one group will be sent to surgery for total thyroidectomy, and their TSH levels will be kept between 0.4-1 with levothyroxine treatment; the other group will be followed under antithyroid drug treatment and their TSH levels will be kept between 0.4-1 also. The smoking habits will be asked. Serum TSH, fT4 levels, Hertelmeter and eye lid opening measurements, clinical activity scores, diplopia will be evaluated monthly; TSH receptor antibody, anti-thyroid peroxidase and anti-thyroglobulin levels will be measured in 3 months intervals for a period of 12 months. |
| NCT01436994 ↗ | Antithyroid Drug Treatment of Thyrotoxicosis in Young People | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | Phase 3 | 2004-07-01 | The investigators aim to establish whether biochemical control during anti-thyroid drug therapy in young people with thyrotoxicosis varies depending upon whether a 'block and replace' or 'dose titration' regimen is used. The investigators will also assess remission rates and the frequency of side-effects in the two treatment groups. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for propylthiouracil
Condition Name
Clinical Trial Locations for propylthiouracil
Trials by Country
Clinical Trial Progress for propylthiouracil
Clinical Trial Phase
Clinical Trial Sponsors for propylthiouracil
Sponsor Name
